Ashwin Balagopal, MD

• Chair, ACTG 5335s
• Investigator ACTG 5329 and ACTG 5334s
• Investigator, Hepatitis Transformative Science Group (Feb 2016)

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of...

The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...

The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable...

IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...

Johns Hopkins University Baltimore-India Clinical Trials Unit